14.16
-0.10
(-0.70%)
May 24 - Close
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 13.94 - 14.24 |
| 52 week | 12.50 - 16.99 |
| Open | 14.24 |
| Vol / Avg. | 71,883.00/228,131.00 |
| Mkt cap | 511.48M |
| P/E | 23.21 |
| Div/yield | - |
| EPS | 0.61 |
| Shares | 36.12M |
| Beta | -0.05 |
| Inst. own | 64% |
Events
Jul 29, 2013
Q2 2013 Emergent BioSolutions Inc. Earnings Release
Jun 3, 2013
Emergent BioSolutions Inc. at Jefferies Global Healthcare Conference
- 9:00AM EDT -
May 23, 2013
Emergent BioSolutions 2013 Annual Shareholders Meeting -
May 16, 2013
Emergent BioSolutions Inc. at Bank of America Merrill Lynch Health Care Conference -
May 10, 2013
Emergent BioSolutions Inc. at Credit Suisse Antibody Day -
May 2, 2013
Q1 2013 Emergent BioSolutions Inc. Earnings Conference Call -
Apr 29, 2013
Q1 2013 Emergent BioSolutions Inc. Earnings Release
Apr 25, 2013
Emergent BioSolutions to Acquire Healthcare Protective Products Division of Bracco Diagnostics Inc. Conference Call -
Mar 7, 2013
Q4 2012 Emergent BioSolutions Inc. Earnings Conference Call -
Mar 4, 2013
Emergent BioSolutions Inc. at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -20.43% | 6.44% |
| Operating margin | -30.97% | 10.63% |
| EBITD margin | - | 18.01% |
| Return on average assets | -6.41% | 3.27% |
| Return on average equity | -7.37% | 5.50% |
| Employees | 877 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 400, 2273 Research Boulevard
ROCKVILLE, MD 20850
United States - Map
+1-301-7951800 (Phone)
+1-301-7951899 (Fax)
ROCKVILLE, MD 20850
United States - Map
+1-301-7951800 (Phone)
+1-301-7951899 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD). The Company�s BioDefense Division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax.
Officers and directors
| Fuad El-Hibri | Executive Chairman of the Board | |
| Daniel J Abdun-Nabi | President, Chief Executive Officer, Director | |
| Robert G Kramer Sr. | Chief Financial Officer, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | |
| Steven N. Chatfield Ph.D. | Executive Vice President - Strategic Investments | |
| Adam Havey | Executive Vice President, President - BioDefense Division | |
| Ronald B Richard | Lead Independent Director | |
| Sue Bailey M.D. | Independent Director | |
| Zsolt Harsanyi Ph.D. | Independent Director | |
| John E. Niederhuber M.D. | Independent Director | |
| Louis W. Sullivan M.D. | Independent Director |